Aoife Maxwell
Overview
Explore the profile of Aoife Maxwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee J, Pollard S, Liu M, Schleich F, Pelaia G, Almonacid C, et al.
Ann Allergy Asthma Immunol
. 2025 Jan;
PMID: 39805551
Background: Some patients with severe asthma have overlapping allergic and eosinophilic phenotypes and may be eligible for anti-eosinophilic or anti-IgE biologics. Objective: This post hoc sub-analysis assessed real-world mepolizumab effectiveness...
2.
Hamy V, Llop C, Yee C, Garcia-Gancedo L, Maxwell A, Chen W, et al.
Sci Rep
. 2023 Oct;
13(1):18311.
PMID: 37880288
Rheumatoid arthritis (RA) is a fluctuating progressive disease requiring frequent symptom assessment for appropriate management. Continuous tracking using digital technologies may provide greater insights of a patient's experience. This prospective...
3.
Pilette C, Canonica G, Chaudhuri R, Chupp G, Lee F, Lee J, et al.
J Allergy Clin Immunol Pract
. 2022 Jun;
10(10):2646-2656.
PMID: 35753668
Background: Patients with severe asthma may require maintenance oral corticosteroids (mOCS) for disease control as well as systemic corticosteroid (SCS) bursts for clinically significant exacerbations. However, mOCS and SCS use...
4.
Pini L, Caruso C, Colantuono S, Bagnasco D, Maxwell A, Price R, et al.
Clin Transl Allergy
. 2021 Oct;
11(8):e12067.
PMID: 34691389
No abstract available.
5.
Harrison T, Canonica G, Chupp G, Lee J, Schleich F, Welte T, et al.
Eur Respir J
. 2020 Aug;
56(4).
PMID: 32817259
Introduction: Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in randomised controlled trials; data on its real-world impact in routine clinical practice are starting to emerge. We assessed the...
6.
Henley Z, Amour A, Barton N, Bantscheff M, Bergamini G, Bertrand S, et al.
J Med Chem
. 2019 Dec;
63(2):638-655.
PMID: 31855425
Optimization of a lead series of PI3Kδ inhibitors based on a dihydroisobenzofuran core led to the identification of potent, orally bioavailable compound . Selectivity profiling of compound showed similar potency...